2018 News Releases

Webcast ImageWebcast
Clovis Oncology, Inc. Earnings Conference Call (Replay)
02/26/18 at 4:30 p.m. ET
Clovis Oncology, Inc. Earnings Conference Call
Monday, February 26, 2018 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
2018 | 2017 | 2016 | 2015 | 2014
03/23/18Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe
BOULDER, Colo.--(BUSINESS WIRE)--Mar. 23, 2018-- Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation fro... 
Printer Friendly Version 
03/23/18CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets
Rubraca offers a new option for women with advanced BRCA mutant ovarian cancer with platinum-sensitive, relapsed or progressive disease, who are unable to tolerate further platinum based chemotherapy First PARP inhibitor recommended for treatment indication in the EU European Commission (EC) formal approval is anticipated Q2 2018 Once approved by the EC, Clovis plans to file a variation to the M... 
Printer Friendly Version 
03/08/18Clovis Oncology Announces Notice of Allowance for Rucaparib High Dosage Strength Tablet Patent with Expiration in 2035
• Claims to be issued cover all commercial dosage strengths of Rubraca® • This will be the 10th Orange Book-listed patent for Rubraca BOULDER, Colo.--(BUSINESS WIRE)--Mar. 8, 2018-- Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the Company has received a Notice of Allowance from the United States Patent and Trademark Office in United States Patent Application 14/828,065 with claims directed to high dosage strength ruc... 
Printer Friendly VersionDownload PDF
03/07/18Clovis Oncology to Present at the Barclays Global Healthcare Conference
BOULDER, Colo.--(BUSINESS WIRE)--Mar. 7, 2018-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the Barclays Global Healthcare Conference on Thursday, March 15, 2018 at 8:00 AM Eastern Time. The conference will be held at the Loews Miami Beach Hotel in Miami. A live webcast of the presentation can be accessed through the investor relations section of the C... 
Printer Friendly VersionDownload PDF
02/26/18Clovis Oncology Announces 2017 Operating Results
First full year of Rubraca® (rucaparib) U.S. sales totaled $55.5M, including $17.0M for the fourth quarter of 2017, with limited third-line BRCA-mutant ovarian cancer treatment label U.S. maintenance treatment indication under review, with April 6, 2018 PDUFA date CHMP positive trend vote communicated for limited treatment indication; formal CHMP vote anticipated in March 2018 ... 
Printer Friendly VersionDownload PDF
02/21/18Clovis Oncology Receives Positive Trend Vote from CHMP in European Regulatory Review for Rucaparib Ovarian Cancer Treatment Indication
The CHMP has communicated a positive trend vote for the rucaparib MAA under review for the treatment of women with advanced BRCA-mutant ovarian cancer and expects to vote on the treatment indication at their scheduled meeting in March 2018 Pending a positive recommendation by CHMP, final approval by the European Commission would follow in Q2 2018 BOULDER, Colo.--(BUSINESS WIRE)--Feb. 21, 2018-- Clovis Oncology... 
Printer Friendly VersionDownload PDF
02/12/18Clovis Oncology to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Webcast Conference Call on February 26
BOULDER, Colo.--(BUSINESS WIRE)--Feb. 12, 2018-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and full year 2017 financial results on Monday, February 26, 2018, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the company’s results in greater detail. The conference call is being webcast and can be accessed from the Clovis... 
Printer Friendly VersionDownload PDF
01/04/18Clovis Oncology to Present at the 36th Annual J.P. Morgan Healthcare Conference
BOULDER, Colo.--(BUSINESS WIRE)--Jan. 4, 2018-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018 at 2:30 PM Pacific Time. The conference will be held at the Westin St. Francis Hotel in San Francisco. A live webcast of the presentation and breakout session can be accessed throu... 
Printer Friendly VersionDownload PDF
Investor Relations and Corporate Communications Contacts
Breanna Burkart
Phone: 303.625.5023
E-mail: bburkart@clovisoncology.com
Anna Sussman
Phone: 303.625.5022
E-mail: asussman@clovisoncology.com